SSI(SZ:002742)2019-04-24 16:00Financial Performance - The company's operating revenue for Q1 2019 was ¥634,065,296.97, representing an increase of 18.94% compared to ¥533,078,703.35 in the same period last year[7]. - The net profit attributable to shareholders was ¥36,007,855.61, up 4.70% from ¥34,392,415.00 year-on-year[7]. - The net profit after deducting non-recurring gains and losses was ¥34,508,048.10, reflecting a growth of 9.62% from ¥31,479,684.82 in the previous year[7]. - The company reported a total comprehensive income of ¥36,631,363.08, down 1.7% from ¥37,280,607.18 in the previous period[41]. - Net profit for the current period was ¥43,830,366.97, representing a slight increase of 2.2% from ¥42,868,141.21 in the previous period[40]. Cash Flow - The net cash flow from operating activities improved significantly to -¥29,587,544.40, a 68.40% reduction in losses compared to -¥93,627,105.20 in the same period last year[7]. - Cash flow from operating activities was ¥611,332,842.35, significantly higher than ¥375,055,567.85 in the previous period, indicating a 63% increase[47]. - The net cash flow from operating activities was -55,822,949.25 yuan, compared to -42,470,910.58 yuan in the previous period, indicating a decline in operational performance[52]. - Cash inflow from financing activities amounted to 118,443,914.02 yuan, an increase from 59,500,000.00 yuan in the previous period[53]. - The net cash flow from financing activities was 39,373,914.41 yuan, compared to -27,362,643.49 yuan in the previous period, showing a significant improvement[53]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,915,567,538.55, down 2.42% from ¥5,037,422,383.23 at the end of the previous year[7]. - Current liabilities decreased from CNY 2,187,871,179.87 to CNY 2,061,229,296.50, a reduction of about 5.77%[31]. - Total liabilities decreased from CNY 3,281,416,446.23 to CNY 3,122,766,552.29, a reduction of about 4.84%[31]. - The company's equity increased from CNY 1,756,005,937.00 to CNY 1,792,800,986.26, an increase of approximately 2.09%[32]. - The total amount of non-operating fund occupation at the end of the reporting period was RMB 375.83 million, accounting for 21.40% of the latest audited net assets[22]. Investments and Future Plans - The company plans to continue investing in the pharmaceutical industry and accelerate its internationalization strategy to enhance profit contributions[18]. - The company aims to maintain stable revenue and profit growth through strategic adjustments and negotiations with government departments regarding mining rights[18]. Operational Efficiency - The cash flow from financing activities showed a substantial improvement, reaching ¥34,192,774.60 compared to -¥28,126,634.23 in the previous year, indicating enhanced operational efficiency[15]. - The company experienced a 44.43% decrease in notes receivable, totaling ¥92,502,137.00, due to an increase in cash collection[15]. - The company experienced a decrease in sales expenses, which fell to ¥6,288,069.21 from ¥7,099,140.24, a reduction of approximately 11.4%[38]. Risks and Challenges - The company faced a risk of not obtaining the renewal of its gypsum mining rights, which could lead to increased production costs and impact operating profits if gypsum needs to be purchased externally[18]. - The company is currently under investigation by the China Securities Regulatory Commission for suspected information disclosure violations, with uncertain outcomes[17].